Syntegon reports 19% sales growth in Q3 2025 driven by pharma innovation

GERMANY—Syntegon Group, a leading partner to the pharmaceutical, biotech, and food industries, has maintained strong growth momentum in the third quarter of 2025.

The company achieved group sales of €448 million (USD 516 million) in Q3, a 19% increase from the prior year, with organic growth contributing 15% to this expansion.

The company’s Pharma business unit led the strong performance, delivering sales growth of 32%, including 20% organic growth.

This impressive result reflects continued customer demand and successful new project wins following the launch of innovative technologies aligned with Syntegon’s growth strategy in 2024.

Adjusted EBITDA for the quarter increased by 37% to €75 million (USD86 million), resulting in an EBITDA margin of 16.7%, up 230 basis points compared to the previous year.

The margin expansion stems from higher volume leverage, continued execution of operational excellence initiatives, and a strategic focus on higher-margin business segments.

Innovation and new technologies played a significant role in Syntegon’s third-quarter performance.

The company’s integrated vial line business accelerated, enabled by the successful integration of Telstar, which Syntegon acquired in Q4 2024.

As part of Syntegon, Telstar has delivered substantial margin improvement and attractive growth in its core freeze dryer business.

Meanwhile, the company recorded strong order intake in its ready-to-use (RTU) syringe business.

Torsten Türling, CEO of Syntegon, noted that the growth and value-creation strategy delivers measurable impact and demonstrates the trust customers place in Syntegon as their strategic lifecycle partner for mission-critical technologies.

He emphasized that the company’s global footprint and innovative technologies position it well to capture long-term growth opportunities in customers’ industries.

For the first nine months of 2025, group sales increased by 14% to €1,272 million (USD 1,464 million), including 11% organic growth.

Adjusted EBITDA rose by 40% to €202 million (USD 232 million), corresponding to a margin of 15.9%, up 300 basis points versus the prior year.

Free cash flow improved by 31% to €102 million (USD117 million) over the same period, supported by disciplined working capital management and targeted capital expenditure investments of 2.6% of sales.

The company anticipates minimal impact from potential headwinds related to global trade developments, particularly U.S. tariffs.

Syntegon plans to mitigate these challenges through countermeasures, its globally balanced supply chain, and long-term customer partnerships.

Additionally, the expansion of production capacities in the U.S. pharmaceutical sector creates further opportunities for the company.

Eros Carletti, CFO of Syntegon, highlighted that the strong Q3 and year-to-date results underline the business’s financial resilience.

Higher volumes in attractive margin segments, combined with seamless project execution and tight cost controls, have enabled the company to achieve robust profitability.

The solid cash flow reinforces financial strength and provides flexibility to continue investing in strategic priorities while driving margin expansion.